https://www.pharmaradar360.com/article/bofa-raises-krystal-biotech-stock-price-target-on-vyjuvek-growth-11786a2e16c395abPharma Surgeen2026-07-13T16:13:25.000ZBofA raises Krystal Biotech stock price target on Vyjuvek growthhttps://www.pharmaradar360.com/article/criteriacaixa-targets-300m-for-biotech-and-tech-by-2030-03fcf8ba89a580ecPharma Surgeen2026-07-13T15:58:38.000ZCriteriaCaixa targets €300M for biotech and tech by 2030https://www.pharmaradar360.com/article/pune-fda-seizes-suspected-adulterated-food-stock-worth-37-61-lakh-across-seven-l-26406810abc8182aPharma Surgeen2026-07-13T15:53:02.000ZPune: FDA Seizes Suspected Adulterated Food Stock Worth ₹37.61 Lakh Across Seven Locationshttps://www.pharmaradar360.com/article/industry-analysis-says-innovative-medicines-deliver-six-fold-return-in-greece-1c95a9c4133dad82Pharma Surgeen2026-07-13T15:45:00.000ZIndustry analysis says innovative medicines deliver six-fold return in Greecehttps://www.pharmaradar360.com/article/fda-s-latest-onshoring-move-homes-in-on-streamlined-facility-registration-foreig-863b180911a9389dPharma Surgeen2026-07-13T15:37:17.000ZFDA's latest onshoring move homes in on streamlined facility registration, foreign plant scrutinyhttps://www.pharmaradar360.com/article/register-to-make-submissions-to-the-mhra-2bf64e65d9b9a3f9Pharma Surgeen2026-07-13T15:34:24.000ZRegister to make submissions to the MHRAhttps://www.pharmaradar360.com/article/germany-approves-healthcare-costs-overhaul-despite-significant-pharma-opposition-392d13fc25f07602Pharma Surgeen2026-07-13T15:17:48.000ZGermany approves healthcare costs overhaul despite significant pharma oppositionhttps://www.pharmaradar360.com/article/here-s-how-much-100-invested-in-state-street-spdr-s-p-biotech-etf-20-years-ago-w-3a4aaa8a7fc82147Pharma Surgeen2026-07-13T15:04:00.000ZHere's How Much $100 Invested In State Street SPDR S&P Biotech ETF 20 Years Ago Would Be Worth Todayhttps://www.pharmaradar360.com/article/ai-enabled-drug-discovery-collaboration-with-veraxa-biotech-to-support-growing-b-98b0460c63c86fa2Pharma Surgeen2026-07-13T14:55:00.000ZAI-enabled drug discovery collaboration with VERAXA biotech to support growing BiTAC® pipelinehttps://www.pharmaradar360.com/article/300-million-for-iberian-biotech-and-deeptech-as-criteriacaixa-rebrands-its-vc-ar-cb37eb5cfb792724Pharma Surgeen2026-07-13T14:50:51.000Z€300 million for Iberian BioTech and DeepTech as CriteriaCaixa rebrands its VC armhttps://www.pharmaradar360.com/article/fda-accepts-nda-for-mezigdomide-combo-in-r-r-multiple-myeloma-b09e100332b1952aPharma Surgeen2026-07-13T14:49:51.000ZFDA Accepts NDA for Mezigdomide Combo in R/R Multiple Myelomahttps://www.pharmaradar360.com/article/biogen-stock-is-upgraded-to-buy-ahead-of-key-alzheimer-s-drug-study-details-b70d1a7e4fab3b63Pharma Surgeen2026-07-13T14:46:00.000ZBiogen Stock Is Upgraded to Buy Ahead of Key Alzheimer’s Drug Study Detailshttps://www.pharmaradar360.com/article/agenus-agen-stock-jumps-13-on-major-340m-financing-agreement-67f434def7d1747cPharma Surgeen2026-07-13T14:42:37.000ZAgenus (AGEN) Stock Jumps 13% on Major $340M Financing Agreementhttps://www.pharmaradar360.com/article/tris-pharma-s-crl-for-narcolepsy-drug-agenus-abandons-phase-3-crc-trial-3d95cfadf89331f4Pharma Surgeen2026-07-13T14:30:00.000ZTris Pharma’s CRL for narcolepsy drug; Agenus abandons Phase 3 CRC trialhttps://www.pharmaradar360.com/article/pharmaceutical-companies-evaluate-financial-and-operational-impact-of-transition-b3998405c487a15fPharma Surgeen2026-07-13T14:22:58.000ZPharmaceutical Companies Evaluate Financial and Operational Impact of Transitioning to Reusable Plastic Palletshttps://www.pharmaradar360.com/article/9-of-the-top-10-pharma-manufacturers-partner-with-redi-health-to-lead-the-next-g-687e9ffbfdb37833Pharma Surgeen2026-07-13T14:15:34.000Z9 of the Top 10 Pharma Manufacturers Partner with Redi Health to Lead the Next-Generation Patient Experiencehttps://www.pharmaradar360.com/article/practical-ai-applications-for-biotech-r-d-ef7a1074e1eb4b6cPharma Surgeen2026-07-13T14:14:00.000ZPractical AI applications for biotech R&Dhttps://www.pharmaradar360.com/article/oncolytics-biotech-shares-climb-ahead-of-planned-fda-meeting-on-reo-033-trial-on-40c4c9d4f610646ePharma Surgeen2026-07-13T14:13:13.000ZOncolytics Biotech Shares Climb Ahead of Planned FDA Meeting on REO 033 Trial (ONCY)https://www.pharmaradar360.com/article/fda-issues-crl-to-elevar-therpaeutics-for-combination-of-rivoceranib-and-camreli-0b540c5f52f6a3f1Pharma Surgeen2026-07-13T14:12:34.000ZFDA Issues CRL to Elevar Therpaeutics for Combination of Rivoceranib and Camrelizumabhttps://www.pharmaradar360.com/article/alopecia-areata-drug-holds-hair-regrowth-after-patients-stop-taking-it-51a36989eaa850ecPharma Surgeen2026-07-13T14:06:31.000ZAlopecia Areata Drug Holds Hair Regrowth After Patients Stop Taking Ithttps://www.pharmaradar360.com/article/kailera-s-oral-obesity-pill-posts-phase-3-gains-fb9cb254da1a8169Pharma Surgeen2026-07-13T14:02:08.000ZKailera’s oral obesity pill posts Phase 3 gainshttps://www.pharmaradar360.com/article/the-uk-and-the-eu-drugs-agency-sign-a-working-arrangement-86aab2205363a2e7Pharma Surgeen2026-07-13T14:02:00.000ZThe UK and the EU Drugs Agency sign a working arrangementhttps://www.pharmaradar360.com/article/medienmitteilung-freihandelsabkommen-schweiz-uk-setzt-klares-zeichen-fur-den-sch-3ff4cfa488ed80caPharma Surgeen2026-07-13T14:00:56.000ZMedienmitteilung: Freihandelsabkommen Schweiz–UK setzt klares Zeichen für den Schutz des geistigen Eigentumshttps://www.pharmaradar360.com/article/defining-supply-chain-impact-when-transitioning-to-reusable-packaging-c40c01d43c23ea82Pharma Surgeen2026-07-13T13:59:25.000ZDefining Supply Chain Impact When Transitioning to Reusable Packaginghttps://www.pharmaradar360.com/article/edgewise-therapeutics-completes-up-to-2-65-billion-sevasemten-sale-to-focus-on-c-5c69845ebb86c9f1Pharma Surgeen2026-07-13T13:55:44.000ZEdgewise Therapeutics Completes Up to $2.65 Billion Sevasemten Sale to Focus on Cardiovascular Pipelinehttps://www.pharmaradar360.com/article/leqembi-autoinjector-matches-iv-drip-from-day-one-aaic-2026-data-show-e70f6a50bad35ecaPharma Surgeen2026-07-13T13:46:53.000ZLeqembi Autoinjector Matches IV Drip From Day One, AAIC 2026 Data Showhttps://www.pharmaradar360.com/article/all-eyes-on-data-on-biogen-s-tau-therapy-e8898fe31b8e1a32Pharma Surgeen2026-07-13T13:41:25.000ZAll eyes on data on Biogen’s tau therapyhttps://www.pharmaradar360.com/article/fda-accepts-biomarin-application-for-full-voxzogo-approval-by-investing-com-5573c8f8ca9700e6Pharma Surgeen2026-07-13T13:40:22.000ZFDA accepts BioMarin application for full VOXZOGO approval By Investing.comhttps://www.pharmaradar360.com/article/12m-pharmaceutical-manufacturing-facility-to-be-built-in-sugar-land-b00066386d96adeaPharma Surgeen2026-07-13T13:36:17.000Z$12M pharmaceutical manufacturing facility to be built in Sugar Landhttps://www.pharmaradar360.com/article/oncolytics-biotech-stock-jumps-on-fda-meeting-plans-for-trial-f83e851bd608249ePharma Surgeen2026-07-13T13:28:22.000ZOncolytics Biotech stock jumps on FDA meeting plans for trialhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-stock-12-month-price-target-raised-to-374-08-im-e4f67e74f83a248aPharma Surgeen2026-07-13T13:20:13.000ZWest Pharmaceutical Services, Inc. Stock 12‑Month Price Target Raised to $374.08, Implies 6% Upsidehttps://www.pharmaradar360.com/article/fda-presents-route-to-improve-operational-efficiency-of-drug-manufacturing-2314e487d787e149Pharma Surgeen2026-07-13T13:12:00.000ZFDA presents route to improve operational efficiency of drug manufacturinghttps://www.pharmaradar360.com/article/pharmaceutical-isolator-market-to-reach-usd-4-13-billion-by-2035-at-10-8-cagr-32b56633e4efc506Pharma Surgeen2026-07-13T13:11:00.000ZPharmaceutical Isolator Market to reach USD 4.13 Billion by 2035 at 10.8% CAGRhttps://www.pharmaradar360.com/article/u-s-food-and-drug-administration-accepts-biomarin-s-supplemental-new-drug-applic-dbc1f184fa253c14Pharma Surgeen2026-07-13T13:05:00.000ZU.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasiahttps://www.pharmaradar360.com/article/biotech-rallies-as-memory-chip-stocks-slide-premarket-431bcf334cde60a8Pharma Surgeen2026-07-13T13:04:42.000ZBiotech Rallies as Memory Chip Stocks Slide Premarkethttps://www.pharmaradar360.com/article/diphtheria-migrant-health-guide-5b603794b2b01ee1Pharma Surgeen2026-07-13T13:00:04.000ZDiphtheria: migrant health guidehttps://www.pharmaradar360.com/article/cosmo-bio-usa-expands-its-portfolio-with-elisa-kits-from-reed-biotech-d5029870461caa75Pharma Surgeen2026-07-13T13:00:00.000ZCosmo Bio USA Expands its Portfolio with ELISA Kits from Reed Biotechhttps://www.pharmaradar360.com/article/vastpro-pharmaceutical-discovers-new-voltage-gated-sodium-channel-blockers-2f3705dc8e9b8f8bPharma Surgeen2026-07-13T13:00:00.000ZVastpro Pharmaceutical discovers new voltage-gated sodium channel blockershttps://www.pharmaradar360.com/article/the-fda-keeps-breaking-its-word-to-dying-patients-3d78bfe18a00e5d9Pharma Surgeen2026-07-13T13:00:00.000ZThe FDA keeps breaking its word to dying patientshttps://www.pharmaradar360.com/article/oncolytics-biotech-reports-fda-regulatory-milestone-and-d683a7ad3a0cfde4Pharma Surgeen2026-07-13T13:00:00.000ZOncolytics Biotech® Reports FDA Regulatory Milestone andhttps://www.pharmaradar360.com/article/iodide-powders-market-forecast-points-higher-toward-2035-driven-by-pharmaceutica-9f8e25d464ff9518Pharma Surgeen2026-07-13T12:56:13.000ZIodide Powders Market Forecast Points Higher Toward 2035, Driven by Pharmaceutical Demand and Feed Fortificationhttps://www.pharmaradar360.com/article/edgewise-therapeutics-completes-sale-of-sevasemten-for-up-to-2-65-billion-streng-0faa7c750edbdf0dPharma Surgeen2026-07-13T12:30:00.000ZEdgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipelinehttps://www.pharmaradar360.com/article/executive-summary-benchmarking-2025-810347b50ddb46f8Pharma Surgeen2026-07-13T12:14:23.000ZExecutive Summary – Benchmarking 2025https://www.pharmaradar360.com/article/cancer-drug-multikine-heads-into-212-patient-global-trial-for-head-and-neck-tumo-89cb77f70dd671e6Pharma Surgeen2026-07-13T12:13:56.000ZCancer drug Multikine heads into 212-patient global trial for head and neck tumorshttps://www.pharmaradar360.com/article/class-2-medicines-recall-beckton-dickson-uk-ltd-chloraprep-1ml-applicator-el-26-6e1352e4be6cfe49Pharma Surgeen2026-07-13T12:03:35.000ZClass 2 Medicines Recall: Beckton Dickson UK Ltd, ChloraPrep 1mL applicator, EL(26)A/34https://www.pharmaradar360.com/article/healthcare-monitor-2025-2026-pharmaceutical-companies-must-better-respond-to-web-dbade2581c2b31caPharma Surgeen2026-07-13T12:03:00.000ZHealthcare Monitor 2025-2026: Pharmaceutical companies must better respond to website quality, target-group-oriented communication, and AI visibilityhttps://www.pharmaradar360.com/article/matinas-biopharma-announces-strategic-business-combination-with-gh-power-to-crea-7645fefe4ad331aePharma Surgeen2026-07-13T12:00:00.000ZMatinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticalshttps://www.pharmaradar360.com/article/ukhsa-updates-heat-health-alerts-across-england-ed2386aedcea3cbcPharma Surgeen2026-07-13T11:48:15.000ZUKHSA updates heat health alerts across Englandhttps://www.pharmaradar360.com/article/cognition-therapeutics-participating-in-fireside-chat-at-b-riley-securities-mind-73844779ac65f0d7Pharma Surgeen2026-07-13T11:37:14.000ZCognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summithttps://www.pharmaradar360.com/article/fda-cancels-food-licenses-of-three-hotels-in-nagpur-f018c1f4288209f9Pharma Surgeen2026-07-13T11:32:09.000ZFDA Cancels Food Licenses of Three Hotels in Nagpurhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-protect-pharmaceutical-corp-otc-prtt-1e97c7f1254a9166Pharma Surgeen2026-07-13T11:31:41.000ZEnterprise value to revenue forward of Protect Pharmaceutical Corp – OTC:PRTThttps://www.pharmaradar360.com/article/puretech-founded-entity-celea-therapeutics-doses-first-patient-in-global-phase-3-ae0f8c7f2405a747Pharma Surgeen2026-07-13T11:29:31.000ZPureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)https://www.pharmaradar360.com/article/celea-therapeutics-doses-first-patient-in-global-phase-3-surpass-ipf-trial-evalu-d7af18c6e6e4b5a6Pharma Surgeen2026-07-13T11:29:31.000ZCelea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)https://www.pharmaradar360.com/article/biotech-stocks-at-52-week-highs-amwl-cue-iccc-srrk-fth-45a5fd33ce42cbd7Pharma Surgeen2026-07-13T11:17:00.000ZBiotech Stocks At 52-Week Highs: AMWL, CUE, ICCC, SRRK, FTHhttps://www.pharmaradar360.com/article/ocugen-announces-binding-term-sheet-for-ocu400-license-deal-in-mena-region-with-1174a28497da65cePharma Surgeen2026-07-13T11:13:00.000ZOcugen Announces Binding Term Sheet for OCU400 License Deal in MENA Region with Roots Pharmaceuticalhttps://www.pharmaradar360.com/article/veraxa-biotech-ag-announces-ai-collaboration-with-ardigen-to-support-bitac-cance-8679c60236dd90b5Pharma Surgeen2026-07-13T11:13:00.000ZVERAXA Biotech AG Announces AI Collaboration with Ardigen to Support BiTAC Cancer Therapeutics Pipelinehttps://www.pharmaradar360.com/article/gene-therapy-for-inherited-blindness-set-for-mena-launch-under-ocugen-roots-pact-19b2fea93c5fdc14Pharma Surgeen2026-07-13T11:02:00.000ZGene therapy for inherited blindness set for MENA launch under Ocugen–Roots pacthttps://www.pharmaradar360.com/article/this-biotech-lets-rare-disease-families-invest-in-its-gene-therapy-db90b2f26e641ab4Pharma Surgeen2026-07-13T11:00:00.000ZThis Biotech Lets Rare-Disease Families Invest In Its Gene Therapyhttps://www.pharmaradar360.com/article/ai-partnership-aims-to-sharpen-cancer-target-selection-at-veraxa-cba6b28832c04b43Pharma Surgeen2026-07-13T11:00:00.000ZAI partnership aims to sharpen cancer target selection at VERAXAhttps://www.pharmaradar360.com/article/fda-backs-pediatric-study-framework-for-armata-s-staph-infection-therapy-ap-sa02-456be7730829a005Pharma Surgeen2026-07-13T11:00:00.000ZFDA backs pediatric study framework for Armata’s Staph infection therapy AP-SA02https://www.pharmaradar360.com/article/2026-363bb9a36499ff1fPharma Surgeen2026-07-13T10:59:32.000ZΑνατιμολόγηση ΜΗΣΥΦΑ 2026 _ Προτεινόμενες τιμές προς διαβούλευσηhttps://www.pharmaradar360.com/article/u-s-food-and-drug-administration-accepts-bristol-myers-squibb-s-new-drug-applica-31f29cb801f26da3Pharma Surgeen2026-07-13T10:59:00.000ZU.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myelomahttps://www.pharmaradar360.com/article/biotech-startup-funding-gap-widens-despite-rebound-in-vc-investment-76c75736cd856400Pharma Surgeen2026-07-13T10:52:51.000ZBiotech startup funding gap widens despite rebound in VC investmenthttps://www.pharmaradar360.com/article/jpmorgan-initiates-coverage-of-legend-biotech-legn-with-neutra-8e480a62464acae7Pharma Surgeen2026-07-13T10:50:16.000ZJPMorgan Initiates Coverage of Legend Biotech (LEGN) with Neutrahttps://www.pharmaradar360.com/article/the-wrong-way-to-compete-with-china-in-biotech-cf60d24e1b539f61Pharma Surgeen2026-07-13T10:35:46.000ZThe Wrong Way To Compete With China in Biotechhttps://www.pharmaradar360.com/article/takeda-pharmaceutical-tak-holder-to-resell-51-579-adss-under-rule-144-9d8fe7dbaec29010Pharma Surgeen2026-07-13T10:33:10.000ZTakeda Pharmaceutical (TAK) holder to resell 51,579 ADSs under Rule 144https://www.pharmaradar360.com/article/8-k-agenus-inc-reports-material-event-7a850300dc6093b2Pharma Surgeen2026-07-13T10:33:10.000Z[8-K] AGENUS INC Reports Material Eventhttps://www.pharmaradar360.com/article/takeda-pharmaceutical-tak-holder-to-sell-4-319-adss-from-rsu-awards-08e695cba9b4bffcPharma Surgeen2026-07-13T10:32:58.000ZTakeda Pharmaceutical (TAK) holder to sell 4,319 ADSs from RSU awardshttps://www.pharmaradar360.com/article/takeda-pharmaceutical-nyse-tak-plans-sale-of-24-887-adss-valued-at-416-850-4e2502ae48df39fePharma Surgeen2026-07-13T10:32:57.000ZTakeda Pharmaceutical (NYSE: TAK) plans sale of 24,887 ADSs valued at $416,850https://www.pharmaradar360.com/article/china-s-pharmaceutical-innovation-30-of-global-drug-pipeline-and-record-deals-in-8b34ba0070daa384Pharma Surgeen2026-07-13T10:31:00.000ZChina’s Pharmaceutical Innovation: 30% of Global Drug Pipeline and Record Deals in 2026 - News and Statisticshttps://www.pharmaradar360.com/article/takeda-pharmaceutical-tak-files-notice-to-sell-7-889-adss-on-nyse-aa17accecc2f6ea0Pharma Surgeen2026-07-13T10:30:24.000ZTakeda Pharmaceutical (TAK) files notice to sell 7,889 ADSs on NYSEhttps://www.pharmaradar360.com/article/takeda-pharmaceutical-tak-holder-to-sell-54-210-adss-after-rsu-vesting-13085ac53373e464Pharma Surgeen2026-07-13T10:30:24.000ZTakeda Pharmaceutical (TAK) holder to sell 54,210 ADSs after RSU vestinghttps://www.pharmaradar360.com/article/trump-purge-at-fda-and-usda-triggers-food-safety-brain-drain-211ed6056a9146daPharma Surgeen2026-07-13T10:29:16.000ZTrump purge at FDA and USDA triggers food safety ‘brain drain’https://www.pharmaradar360.com/article/tethis-expands-global-access-to-smartbiosurface-through-new-channel-partners-4174ac26287ef939Pharma Surgeen2026-07-13T10:28:38.000ZTethis expands global access to SmartBioSurface through new channel partnershttps://www.pharmaradar360.com/article/should-you-invest-in-the-vaneck-biotech-etf-bbh-382b2290b1dd0c20Pharma Surgeen2026-07-13T10:20:01.000ZShould You Invest in the VanEck Biotech ETF (BBH)?https://www.pharmaradar360.com/article/la-aemps-deja-de-emitir-la-comunicacion-de-la-decision-para-las-variaciones-ia-i-4a324b815286ffb5Pharma Surgeen2026-07-13T10:19:02.000ZLa AEMPS deja de emitir la comunicación de la decisión para las variaciones IA/IAin en procedimientos europeos en los que actúa como Estado Miembro Concernidohttps://www.pharmaradar360.com/article/pharmaceutical-direct-to-patient-distribution-models-outpace-existing-safety-ove-7062295955b47536Pharma Surgeen2026-07-13T10:17:32.000ZPharmaceutical Direct-to-Patient Distribution Models Outpace Existing Safety Oversight Infrastructurehttps://www.pharmaradar360.com/article/144-takeda-pharmaceutical-co-ltd-sec-filing-53ad25fdd21f90b2Pharma Surgeen2026-07-13T10:16:04.000Z[144] TAKEDA PHARMACEUTICAL CO LTD SEC Filinghttps://www.pharmaradar360.com/article/patient-safety-commissioner-annual-report-2025-to-2026-429f73f977e61214Pharma Surgeen2026-07-13T10:11:40.000ZPatient Safety Commissioner annual report 2025 to 2026https://www.pharmaradar360.com/article/cder-proposes-to-withdraw-approval-of-tavneos-a685cf2b34395291Pharma Surgeen2026-07-13T10:09:43.000ZCDER proposes to withdraw approval of TAVNEOShttps://www.pharmaradar360.com/article/goldman-sachs-initiates-erasca-stock-coverage-as-early-stage-biotech-84a525194ab45e74Pharma Surgeen2026-07-13T10:06:07.000ZGoldman Sachs initiates Erasca stock coverage as early-stage biotechhttps://www.pharmaradar360.com/article/agenus-announces-oversubscribed-private-placement-of-up-to-340-million-to-advanc-407a74298b4b551ePharma Surgeen2026-07-13T10:00:00.000ZAgenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancerhttps://www.pharmaradar360.com/article/denmark-urged-to-rework-confidential-drug-pricing-pilot-9d966d7ddee2652dPharma Surgeen2026-07-13T09:56:21.000ZDenmark urged to rework confidential drug pricing pilothttps://www.pharmaradar360.com/article/regulatory-round-up-13-july-2026-2673b3c88e709908Pharma Surgeen2026-07-13T09:56:21.000ZRegulatory round-up: 13 July 2026https://www.pharmaradar360.com/article/iqirvo-broadens-liver-disease-case-with-phase-iii-result-ef6390f92dd1ce2cPharma Surgeen2026-07-13T09:56:15.000ZIqirvo broadens liver disease case with Phase III resulthttps://www.pharmaradar360.com/article/immunoglobulin-when-to-use-2bc3407cfc7e587bPharma Surgeen2026-07-13T09:53:35.000ZImmunoglobulin: when to usehttps://www.pharmaradar360.com/article/cosmos-pharmaceutical-corporation-provides-dividend-guidance-for-the-fiscal-year-8bdfe5a25bb87ae4Pharma Surgeen2026-07-13T09:50:56.000ZCOSMOS Pharmaceutical Corporation Provides Dividend Guidance for the Fiscal Year Ending May 31, 2027https://www.pharmaradar360.com/article/cambridge-biotech-files-for-ipo-as-it-awaits-fda-decision-on-sleep-apnea-pill-e9e52c363462e419Pharma Surgeen2026-07-13T09:48:00.000ZCambridge biotech files for IPO as it awaits FDA decision on sleep apnea pillhttps://www.pharmaradar360.com/article/the-wrong-way-to-compete-with-china-in-biotech-b5494be834b4db15Pharma Surgeen2026-07-13T09:44:09.000ZThe Wrong Way To Compete With China in Biotechhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-teva-position-increased-by-sequoia-financial-84f75e221ab3ce09Pharma Surgeen2026-07-13T09:40:49.000ZTeva Pharmaceutical Industries Ltd. $TEVA Position Increased by Sequoia Financial Advisors LLChttps://www.pharmaradar360.com/article/cosmos-pharmaceutical-corporation-provides-consolidated-earnings-guidance-for-th-51d97f47c0cb23c1Pharma Surgeen2026-07-13T09:36:23.000ZCOSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the First Half and Full Year of the Fiscal Year Ending May 31, 2027https://www.pharmaradar360.com/article/fedex-launches-dedicated-life-sciences-organisation-3a9b460d8062b4f5Pharma Surgeen2026-07-13T09:23:44.000ZFedEx launches dedicated life sciences organisationhttps://www.pharmaradar360.com/article/signifor-7ee7a150bce85a2ePharma Surgeen2026-07-13T09:09:10.000ZSigniforhttps://www.pharmaradar360.com/article/takeda-pharmaceutical-tak-launches-plasma-ecosystem-initiative-in-indonesia-38ff4cb8769f6c54Pharma Surgeen2026-07-13T09:03:23.000ZTakeda Pharmaceutical (TAK) Launches Plasma Ecosystem Initiative in Indonesiahttps://www.pharmaradar360.com/article/returns-matter-nutx-214-cort-145-gkos-97-were-these-biotech-stocks-in-your-portf-f71315ad4b43cb61Pharma Surgeen2026-07-13T08:57:00.000ZReturns Matter: NUTX +214%, CORT +145%, GKOS +97% - Were These Biotech Stocks In Your Portfolio?https://www.pharmaradar360.com/article/fda-proposal-to-modernize-drug-manufacturing-registration-2e60627b7fbaebb9Pharma Surgeen2026-07-13T08:51:17.000ZFDA proposal to modernize drug manufacturing registrationhttps://www.pharmaradar360.com/article/erie-clinical-trial-for-eye-medicine-gives-pittsburgh-area-man-hope-db95bd958028dfb1Pharma Surgeen2026-07-13T08:45:00.000ZErie clinical trial for eye medicine gives Pittsburgh-area man hopehttps://www.pharmaradar360.com/article/appeal-by-huaheng-biotech-group-against-eu-duties-on-chinese-valine-released-3539550498971431Pharma Surgeen2026-07-13T08:36:00.000ZAppeal by Huaheng biotech group against EU duties on Chinese valine releasedhttps://www.pharmaradar360.com/article/dhsc-senior-officials-business-expenses-hospitality-and-meetings-october-to-dece-aad24e37abeac595Pharma Surgeen2026-07-13T08:30:40.000ZDHSC: senior officials’ business expenses, hospitality and meetings, October to December 2025https://www.pharmaradar360.com/article/building-the-foundation-for-the-orchestrated-lab-of-the-future-1d7f8f04904cb0faPharma Surgeen2026-07-13T08:19:55.000ZBuilding the foundation for the orchestrated lab of the futurehttps://www.pharmaradar360.com/article/jpmorgan-resumes-legend-biotech-stock-coverage-with-neutral-rating-b2469850d4f2f49cPharma Surgeen2026-07-13T08:17:46.000ZJPMorgan resumes Legend Biotech stock coverage with neutral ratinghttps://www.pharmaradar360.com/article/cabinet-launches-plan-to-attract-foreign-workers-for-ai-biotech-9b6f81d337293545Pharma Surgeen2026-07-13T08:16:54.000ZCabinet launches plan to attract foreign workers for AI, biotechhttps://www.pharmaradar360.com/article/in8bio-publishes-positive-phase-1-gbm-data-0d5ac6621bfa4670Pharma Surgeen2026-07-13T08:04:49.000ZIN8bio Publishes Positive Phase 1 GBM Datahttps://www.pharmaradar360.com/article/leo-pharma-reports-positive-phase-2-tralokinumab-results-ae1c879a37b639aaPharma Surgeen2026-07-13T08:01:33.000ZLEO Pharma Reports Positive Phase 2 Tralokinumab Resultshttps://www.pharmaradar360.com/article/once-monthly-vwd-shot-from-incyte-slashes-bleeding-in-early-trial-bec62739f4c03769Pharma Surgeen2026-07-13T08:00:00.000ZOnce‑monthly VWD shot from Incyte slashes bleeding in early trialhttps://www.pharmaradar360.com/article/drugmaker-vertex-spends-10b-to-buy-biotech-firm-to-expand-rare-disease-offerings-935dac17098ec67aPharma Surgeen2026-07-13T08:00:00.000ZDrugmaker Vertex spends $10B to buy biotech firm to expand rare-disease offeringshttps://www.pharmaradar360.com/article/top-emerging-biotech-hubs-in-2026-937a81aaf901e194Pharma Surgeen2026-07-13T07:59:31.000ZTop emerging biotech hubs in 2026https://www.pharmaradar360.com/article/candriam-s-c-a-makes-new-investment-in-teva-pharmaceutical-industries-ltd-teva-1ba1050e89209392Pharma Surgeen2026-07-13T07:54:19.000ZCandriam S.C.A. Makes New Investment in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/fda-fast-track-designation-for-arialys-anti-nmda-therapy-49e02d047cad66cePharma Surgeen2026-07-13T07:48:44.000ZFDA Fast-Track Designation for Arialys' Anti-NMDA Therapyhttps://www.pharmaradar360.com/article/mbrx-q1-2026-earnings-wider-than-expected-loss-as-clinical-stage-biotech-continu-0f68b61f53b627e6Pharma Surgeen2026-07-13T07:41:15.000ZMBRX Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Biotech Continues Pipeline Developmenthttps://www.pharmaradar360.com/article/puretech-subsidiary-celea-begins-phase-3-ipf-study-comparing-deupirfenidone-with-0e9795825e580c96Pharma Surgeen2026-07-13T07:16:27.000ZPureTech Subsidiary Celea Begins Phase 3 IPF Study Comparing Deupirfenidone With Standard Therapy (PRTC)https://www.pharmaradar360.com/article/dimerix-asx-dxb-shares-slip-is-the-market-underestimating-the-biotechnology-comp-3e289aaf1d86cad7Pharma Surgeen2026-07-13T07:13:00.000ZDimerix (ASX:DXB) Shares Slip: Is the Market Underestimating the Biotechnology Company's Clinical Pipeline?https://www.pharmaradar360.com/article/price-to-sales-forward-of-tibet-rhodiola-pharmaceutical-holding-co-class-a-sse-6-0f9fb859fd23ce23Pharma Surgeen2026-07-13T07:11:42.000ZPrice to sales forward of Tibet Rhodiola Pharmaceutical Holding Co. Class A – SSE:600211https://www.pharmaradar360.com/article/navigating-the-new-eu-pharmaceutical-legislation-key-implications-for-pediatric-907a3e9ad068852bPharma Surgeen2026-07-13T07:10:08.000ZNavigating The New EU Pharmaceutical Legislation Key Implications For Pediatric Drug Developmenthttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-kintor-pharmaceutical-ltd-otc-kntpf-0f48578711f14795Pharma Surgeen2026-07-13T07:06:10.000ZEnterprise value to EBITDA forward of KINTOR PHARMACEUTICAL LTD. – OTC:KNTPFhttps://www.pharmaradar360.com/article/guidebook-on-channel-partner-training-medical-devices-india-c350baf6b0786ffcPharma Surgeen2026-07-13T07:01:41.000ZGuidebook on Channel Partner Training – Medical Devices (India)https://www.pharmaradar360.com/article/jemperli-dostarlimab-achieves-sustained-clinical-complete-responses-in-dmmr-msi-13a9516017afc942Pharma Surgeen2026-07-13T07:00:45.000ZJemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancerhttps://www.pharmaradar360.com/article/u-s-fda-approves-padcev-plus-keytruda-as-neoadjuvant-and-adjuvant-treatment-for-3fd76facf2c83cd4Pharma Surgeen2026-07-13T06:58:36.000ZU.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibilityhttps://www.pharmaradar360.com/article/aribio-receives-remaining-50-mil-payment-from-fosun-for-oral-alzheimer-s-drug-95378eaf37fea4f1Pharma Surgeen2026-07-13T06:51:34.000ZAriBio receives remaining $50 mil. payment from Fosun for oral Alzheimer’s drughttps://www.pharmaradar360.com/article/maharashtra-fda-orders-recall-of-2-45-crore-worth-of-aciloc-medicines-over-confu-5222cef3f52e6c25Pharma Surgeen2026-07-13T06:30:02.000ZMaharashtra FDA Orders Recall of ₹2.45 Crore Worth of Aciloc Medicines Over Confusing Brand Nameshttps://www.pharmaradar360.com/article/table-cosmos-pharmaceutical-2025-26-parent-results-d81e119bf812444bPharma Surgeen2026-07-13T06:30:00.000ZTABLE-Cosmos Pharmaceutical -2025/26 parent resultshttps://www.pharmaradar360.com/article/cosmos-pharmaceutical-sales-and-profits-rose-on-store-growth-with-fy2027-guidanc-69f8e8282d4d71ffPharma Surgeen2026-07-13T06:30:00.000ZCOSMOS Pharmaceutical: Sales and profits rose on store growth, with FY2027 guidance for higher sales and dividendshttps://www.pharmaradar360.com/article/hlb-plunges-as-fda-rejects-liver-cancer-drug-company-pursues-rapid-reapproval-ch-3c5495818305dacePharma Surgeen2026-07-13T06:27:00.000ZHLB plunges as FDA rejects liver cancer drug; company pursues rapid reapproval - CHOSUNBIZhttps://www.pharmaradar360.com/article/fda-advisory-no-2026-0778-public-health-warning-against-the-purchase-and-use-of-c102d3ab80f15a7fPharma Surgeen2026-07-13T06:20:52.000ZFDA Advisory No.2026-0778 || Public Health Warning Against the Purchase and Use of the Unregistered Drug Product “STUNMEDICAL Line Fill Sub-Q Cross Linked Hyaluronic Acid with Lidocaine 1.0 mL”https://www.pharmaradar360.com/article/celea-doses-first-patient-in-phase-3-ipf-drug-trial-by-investing-com-5b73622c231c4e19Pharma Surgeen2026-07-13T06:09:30.000ZCelea doses first patient in phase 3 IPF drug trial By Investing.comhttps://www.pharmaradar360.com/article/price-to-book-forward-of-trinity-biotech-plc-sponsored-adr-fwb-trb0-76312bd1313a95b4Pharma Surgeen2026-07-13T06:08:07.000ZPrice to book forward of Trinity Biotech plc Sponsored ADR – FWB:TRB0https://www.pharmaradar360.com/article/celea-doses-first-patient-in-phase-3-ipf-drug-trial-by-investing-com-d03ecf3ea4db729aPharma Surgeen2026-07-13T06:07:16.000ZCelea doses first patient in phase 3 IPF drug trial By Investing.comhttps://www.pharmaradar360.com/article/celea-therapeutics-doses-first-patient-in-global-phase-3-surpass-ipf-trial-evalu-5475e15bcbd5f51bPharma Surgeen2026-07-13T06:00:00.000ZCelea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)https://www.pharmaradar360.com/article/puretech-founded-entity-celea-therapeutics-doses-first-patient-in-global-phase-3-2a8328817d79f2dfPharma Surgeen2026-07-13T06:00:00.000ZPureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)https://www.pharmaradar360.com/article/third-crl-for-elevar-hengrui-s-liver-cancer-combo-regimen-over-manufacturing-iss-3b737e2893be2653Pharma Surgeen2026-07-13T05:34:56.000ZThird CRL For Elevar/Hengrui’s Liver Cancer Combo Regimen Over Manufacturing Issueshttps://www.pharmaradar360.com/article/paradigm-biopharmaceuticals-issues-3-million-paraad-convertible-notes-at-usd-1-0-d8b6adc7bf311a50Pharma Surgeen2026-07-13T05:03:08.000ZParadigm Biopharmaceuticals Issues 3 Million PARAAD Convertible Notes at USD $1.00 Each on 13 July 2026https://www.pharmaradar360.com/article/krystal-biotech-stock-and-2-biotech-names-with-pipeline-catalysts-bb5d1753c3f6974dPharma Surgeen2026-07-13T05:02:39.000ZKrystal Biotech Stock And 2 Biotech Names With Pipeline Catalystshttps://www.pharmaradar360.com/article/fda-drug-approval-decisions-expected-in-august-2026-ff53f4bf744c6432Pharma Surgeen2026-07-13T04:00:00.000ZFDA Drug Approval Decisions Expected in August 2026https://www.pharmaradar360.com/article/bemotrizinol-exploring-the-newly-approved-sunscreen-active-ingredient-79a2cb8fac0548eePharma Surgeen2026-07-13T04:00:00.000ZBemotrizinol: Exploring the Newly Approved Sunscreen Active Ingredienthttps://www.pharmaradar360.com/article/fda-orders-recall-of-2-45-crore-worth-of-aciloc-plus-medicines-over-risk-of-medi-cbf415e9fe70b2e1Pharma Surgeen2026-07-13T03:50:02.000ZFDA Orders Recall of ₹2.45 Crore Worth of Aciloc Plus Medicines Over Risk of Medication Confusionhttps://www.pharmaradar360.com/article/paradigm-secures-fresh-funds-to-advance-phase-3-knee-osteoarthritis-trial-e94eac2b0764f251Pharma Surgeen2026-07-13T03:32:23.000ZParadigm Secures Fresh Funds to Advance Phase 3 Knee Osteoarthritis Trialhttps://www.pharmaradar360.com/article/paradigm-biopharmaceuticals-issues-3-million-convertible-notes-at-usd-1-00-each-9e0a7c7b7ac4807cPharma Surgeen2026-07-13T03:28:09.000ZParadigm Biopharmaceuticals Issues 3 Million Convertible Notes at USD $1.00 Each, Advancing US$27M Phase 3 OA Trial Fundinghttps://www.pharmaradar360.com/article/astrazeneca-licenses-respiratory-drug-from-sino-biopharma-in-potential-1-9-billi-31a778675fa010edPharma Surgeen2026-07-13T03:22:16.000ZAstraZeneca licenses respiratory drug from Sino Biopharma in potential $1.9 billion dealhttps://www.pharmaradar360.com/article/yakkyokukata-press-release-regarding-international-activities-related-to-pharmac-dd2e305ac4516e25Pharma Surgeen2026-07-13T03:00:00.000Z[YAKKYOKUKATA]Press Release regarding international activities related to Pharmacopoeia postedhttps://www.pharmaradar360.com/article/shinsa-checklist-for-quality-related-documents-for-biotechnology-products-derive-e64cdc015432ccc3Pharma Surgeen2026-07-13T03:00:00.000Z[SHINSA]Checklist for Quality-Related Documents for Biotechnology Products Derived from Cell Lines of Human or Animal Origin at the Time of Initial Clinical Trial Notification（Early Consideration）posted.https://www.pharmaradar360.com/article/daewoong-s-nabota-tops-1tri-in-cumulative-sales-fuels-global-aesthetics-ambition-8225051eaa75f730Pharma Surgeen2026-07-13T02:52:16.000ZDaewoong's Nabota tops ₩1tri. in cumulative sales, fuels global aesthetics ambitionshttps://www.pharmaradar360.com/article/aribio-has-received-all-60-million-about-90-billion-won-in-advance-of-options-un-7b67f4d2d1762b22Pharma Surgeen2026-07-13T02:17:27.000ZAribio has received all $60 million (about 90 billion won) in advance of options under the global co..https://www.pharmaradar360.com/article/south-korea-approves-wainua-autoinjector-for-hereditary-amyloid-neuropathy-chosu-c174a6d12beb78b8Pharma Surgeen2026-07-13T00:15:00.000ZSouth Korea approves Wainua autoinjector for hereditary amyloid neuropathy - CHOSUNBIZhttps://www.pharmaradar360.com/article/aribio-receives-full-upfront-payment-from-fosun-pharma-for-alzheimer-s-drug-deal-9a9bf755a52ebf3ePharma Surgeen2026-07-13T00:06:00.000ZAriBio Receives Full Upfront Payment From Fosun Pharma for Alzheimer's Drug Dealhttps://www.pharmaradar360.com/article/novo-nordisk-filed-form-6-k-9456245b24c6bd8aPharma Surgeen2026-07-13T00:00:00.000ZNovo Nordisk filed Form 6-Khttps://www.pharmaradar360.com/article/gsk-filed-form-6-k-7a58e52555c615e2Pharma Surgeen2026-07-13T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/santen-and-kyorin-announce-joint-marketing-agreement-in-japan-for-allergic-conju-5295b94aa4c50871Pharma Surgeen2026-07-13T00:00:00.000ZSanten and KYORIN announce joint marketing agreement in Japan for allergic conjunctivitis treatment Alesion® Eyelid Cream 0.5%https://www.pharmaradar360.com/article/otsuka-foods-to-revise-prices-of-some-products-new-prices-to-take-effect-with-de-e8963840638a34d9Pharma Surgeen2026-07-13T00:00:00.000ZOtsuka Foods to Revise Prices of Some Products New Prices to Take Effect with Deliveries as of September 1, 2026https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-df698cc367e3b6aePharma Surgeen2026-07-13T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-0f7c56e36893d9b9Pharma Surgeen2026-07-13T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-6541e7269bbdd8b7Pharma Surgeen2026-07-13T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-b80a75c1ed8cb69ePharma Surgeen2026-07-13T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-f1be1c162d2e3167Pharma Surgeen2026-07-13T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-3e71422cefc22fb6Pharma Surgeen2026-07-13T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-dc583a7e2aba0874Pharma Surgeen2026-07-13T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-7350eb2add4d1b69Pharma Surgeen2026-07-13T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-4840b7fe80a863a9Pharma Surgeen2026-07-13T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-ca264b834763e540Pharma Surgeen2026-07-13T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-111049014b567128Pharma Surgeen2026-07-13T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-1b09add30f399f9cPharma Surgeen2026-07-13T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-cb027674dd41a929Pharma Surgeen2026-07-13T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-d4b747af48636784Pharma Surgeen2026-07-13T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/drug-establishment-registration-and-drug-listing-requirements-for-establishments-e5bea87722573411Pharma Surgeen2026-07-13T00:00:00.000ZDrug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishmentshttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-abb1b0ff5618e0d9Pharma Surgeen2026-07-13T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-public-comment-requ-c1c34b64c042fdb0Pharma Surgeen2026-07-13T00:00:00.000ZAgency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: Maternal and Child Health Bureau Performance Measures for Discretionary Grant Information System, OMB No. 0915-0298-Revisionhttps://www.pharmaradar360.com/article/proposed-data-collection-submitted-for-public-comment-and-recommendations-e73a69133ad43bcbPharma Surgeen2026-07-13T00:00:00.000ZProposed Data Collection Submitted for Public Comment and Recommendationshttps://www.pharmaradar360.com/article/agency-forms-undergoing-paperwork-reduction-act-review-f5e567b028afbb3cPharma Surgeen2026-07-13T00:00:00.000ZAgency Forms Undergoing Paperwork Reduction Act Reviewhttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meeting-ac4662fc93dde211Pharma Surgeen2026-07-13T00:00:00.000ZCenter For Scientific Review; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/national-human-genome-research-institute-notice-of-meeting-ea0684d5d0362783Pharma Surgeen2026-07-13T00:00:00.000ZNational Human Genome Research Institute; Notice of Meetinghttps://www.pharmaradar360.com/article/new-global-report-outlines-strategies-to-improve-hematologic-care-for-women-8d55736043b3f7bcPharma Surgeen2026-07-13T00:00:00.000ZNew Global Report Outlines Strategies to Improve Hematologic Care for Womenhttps://www.pharmaradar360.com/article/zopapogene-imadenovec-drba-for-recurrent-respiratory-papillomatosis-43dbfa2307425b27Pharma Surgeen2026-07-13T00:00:00.000ZZopapogene Imadenovec-Drba for Recurrent Respiratory Papillomatosis.https://www.pharmaradar360.com/article/a-meta-analysis-of-randomized-controlled-trials-of-functional-magnetic-resonance-6d3aadd9214c4884Pharma Surgeen2026-07-13T00:00:00.000ZA Meta-analysis of Randomized Controlled Trials of Functional Magnetic Resonance Imaging Neurofeedback for Training of Attention and Related Cognitive Functionshttps://www.pharmaradar360.com/article/acute-myocardial-infarction-in-young-adults-a-systematic-review-of-epidemiology-d56ba8f68c1110c8Pharma Surgeen2026-07-13T00:00:00.000ZAcute Myocardial Infarction in Young Adults: A Systematic Review of Epidemiology, Risk Factors, Clinical Features, Management, and Outcomeshttps://www.pharmaradar360.com/article/effects-of-custom-made-3d-printed-insoles-on-foot-and-body-alignment-in-stroke-s-fdf8cad7b614ae1bPharma Surgeen2026-07-13T00:00:00.000ZEffects of custom-made 3D-printed insoles on foot and body alignment in stroke survivors: an exploratory pilot randomized controlled trialhttps://www.pharmaradar360.com/article/the-health-belief-model-the-healthy-eating-habits-among-11th-grade-high-school-s-fc5a135942328289Pharma Surgeen2026-07-13T00:00:00.000ZThe Health Belief Model: The Healthy Eating Habits Among 11th-grade High School Students in Health Sciences Clusterhttps://www.pharmaradar360.com/article/the-correlation-between-physical-activity-and-fasting-blood-glucose-levels-among-c874d4c2e3e01bb4Pharma Surgeen2026-07-13T00:00:00.000ZThe Correlation Between Physical Activity And Fasting Blood Glucose Levels Among Employees of Universitas Swadaya Gunung Jati: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/focus-on-rare-tracheal-pathologies-you-should-not-miss-91af6d79c22d56ebPharma Surgeen2026-07-13T00:00:00.000ZFocus on Rare Tracheal Pathologies You Should Not Misshttps://www.pharmaradar360.com/article/different-models-of-everyday-physical-activity-and-occurrence-of-falls-among-com-ef32484974fc5c3bPharma Surgeen2026-07-13T00:00:00.000ZDifferent Models of Everyday Physical Activity and Occurrence of Falls Among Community-Dwelling Older Adults and Middle-Aged Citizenshttps://www.pharmaradar360.com/article/cognitive-impairment-and-dysphagia-associated-with-postoperative-hydrocephalus-s-b50509d74a2c73a9Pharma Surgeen2026-07-13T00:00:00.000ZCognitive Impairment and Dysphagia Associated with Postoperative Hydrocephalus Secondary to Cerebrospinal Fluid Leakage After C1–2 Fusion: A Case Reporthttps://www.pharmaradar360.com/article/clinical-and-surgical-risk-factors-for-wound-healing-disorders-following-non-ins-04c98e384cc70ec1Pharma Surgeen2026-07-13T00:00:00.000ZClinical and Surgical Risk Factors for Wound Healing Disorders Following Non-Instrumented Lumbar Spine Surgery Using Penalized Regression Analysishttps://www.pharmaradar360.com/article/time-to-rethink-ics-dosing-in-pursuit-of-asthma-clinical-remission-high-dose-ics-2892f284aba76a45Pharma Surgeen2026-07-13T00:00:00.000ZTime to Rethink ICS Dosing in Pursuit of Asthma Clinical Remission: High-Dose ICS/LABA May Restore Short-Term Asthma Control When Medium Doses Failhttps://www.pharmaradar360.com/article/targeting-the-rsv-and-hmpv-l-protein-cryo-em-and-structure-based-approaches-to-a-593dad7ead198096Pharma Surgeen2026-07-13T00:00:00.000ZTargeting the RSV and hMPV L Protein: Cryo-EM and Structure-Based Approaches to Antiviral Drug Discoveryhttps://www.pharmaradar360.com/article/clinical-heterogeneity-and-diagnostic-challenges-in-cask-related-neurodevelopmen-99ad699c09ec3e5cPharma Surgeen2026-07-13T00:00:00.000ZClinical heterogeneity and diagnostic challenges in CASK-related neurodevelopmental disorders: a longitudinal observational studyhttps://www.pharmaradar360.com/article/effects-of-statins-on-functional-capacity-and-cardiac-remodeling-in-patients-wit-267f53da5f7e6c22Pharma Surgeen2026-07-13T00:00:00.000ZEffects of statins on functional capacity and cardiac remodeling in patients with heart failure and preserved ejection fraction: a randomized open-label pilot trialhttps://www.pharmaradar360.com/article/prognosis-of-pediatric-hepatic-wilson-disease-with-atp7b-loss-of-function-varian-c838a20357937fdaPharma Surgeen2026-07-13T00:00:00.000ZPrognosis of pediatric hepatic Wilson disease with ATP7B loss of function variantshttps://www.pharmaradar360.com/article/clinical-performance-of-nitrous-oxide-inhalation-versus-intravenous-sedation-in-41db06b9b55fc7a2Pharma Surgeen2026-07-13T00:00:00.000ZClinical Performance of Nitrous Oxide Inhalation versus Intravenous Sedation in Outpatient Dental Surgery: Efficacy and Safety Outcomeshttps://www.pharmaradar360.com/article/clinical-efficacy-and-safety-of-3d-miniplate-fixation-for-parasymphyseal-and-ang-b3cfe502b3026cd7Pharma Surgeen2026-07-13T00:00:00.000ZClinical Efficacy and Safety of 3D Miniplate Fixation for Parasymphyseal and Angle Fractures of the Mandible: A Prospective Studyhttps://www.pharmaradar360.com/article/prevalence-and-clinical-characteristics-of-psychodermatoses-among-patients-visit-86ea703fbc4a304aPharma Surgeen2026-07-13T00:00:00.000ZPrevalence and Clinical Characteristics of Psychodermatoses among Patients Visiting Dermatology Outpatient Department in a Tertiary Level Hospital in Bangladeshhttps://www.pharmaradar360.com/article/deep-learning-in-chest-x-ray-analysis-advancing-diagnostic-accuracy-workflow-eff-4240e806ecc3b541Pharma Surgeen2026-07-13T00:00:00.000ZDeep Learning in Chest X-ray Analysis: Advancing Diagnostic Accuracy, Workflow Efficiency, and Environmental Sustainabilityhttps://www.pharmaradar360.com/article/high-resolution-computed-tomography-assessment-of-pulmonary-artery-diameters-in-d26a3456bd161a0dPharma Surgeen2026-07-13T00:00:00.000ZHigh Resolution Computed Tomography Assessment of Pulmonary Artery Diameters in Chronic Obstructive Pulmonary Disease: A Cross-Sectional Comparative Studyhttps://www.pharmaradar360.com/article/coracohumeral-ligament-stretching-is-efficient-in-enhancing-the-outward-rotation-e4212c16db8e0cbaPharma Surgeen2026-07-13T00:00:00.000ZCoracohumeral ligament stretching is efficient in enhancing the outward rotation and pain in Adhesive Capsulitis, illustrating relatively better outcomes compared to conventional capsular stretchinghttps://www.pharmaradar360.com/article/quality-by-design-based-optimization-of-betamethasone-dipropionate-loaded-nanost-59b1f7e14c9884a3Pharma Surgeen2026-07-13T00:00:00.000ZQuality by Design-Based Optimization of Betamethasone Dipropionate-Loaded Nanostructured Lipid Carrier Nanogel for Topical Anti-Inflammatory Drug Deliveryhttps://www.pharmaradar360.com/article/a-chromatographic-method-development-and-validation-for-tofacitinib-citrate-and-f6da21b549275015Pharma Surgeen2026-07-13T00:00:00.000ZA Chromatographic Method Development and Validation for Tofacitinib Citrate and Baricitinib Using RGB And GREEN Pechhttps://www.pharmaradar360.com/article/formulation-and-evaluation-of-lecithin-containing-herbal-cream-c691d4795f066e93Pharma Surgeen2026-07-13T00:00:00.000ZFormulation and Evaluation of Lecithin Containing Herbal Creamhttps://www.pharmaradar360.com/article/a-review-on-resmetirom-an-oral-thyroid-hormone-receptor-agonist-for-the-treatmen-45e75c79a23a2723Pharma Surgeen2026-07-13T00:00:00.000ZA Review on Resmetirom: An Oral Thyroid Hormone Receptor-β Agonist for the Treatment of Metabolically dysfunction-Associated Steatohepatitis (MASH)https://www.pharmaradar360.com/article/hepatitis-b-virus-in-pakistan-serological-marker-prevalence-clinical-correlates-5b6f24e40a0ac22dPharma Surgeen2026-07-13T00:00:00.000ZHepatitis B virus in Pakistan: serological marker prevalence, clinical correlates, and genotype-informed interpretationhttps://www.pharmaradar360.com/article/self-reported-adverse-drug-reactions-to-dolutegravir-based-first-line-antiretrov-6aa8ff94b1783a59Pharma Surgeen2026-07-13T00:00:00.000ZSelf-reported adverse drug reactions to Dolutegravir-Based First-Line Antiretroviral Therapy and associated factors in Ethiopian patients: A Cross-sectional studyhttps://www.pharmaradar360.com/article/clinical-workload-dimensions-multidimensional-physician-well-being-and-turnover-053659c2e6bc22afPharma Surgeen2026-07-13T00:00:00.000ZClinical workload dimensions, multidimensional physician well-being, and turnover intention across primary healthcare facilities and hospitals in China: a cross-sectional studyhttps://www.pharmaradar360.com/article/the-high-volume-opd-problem-why-indian-clinical-documentation-requires-a-purpose-5d39173f48c00979Pharma Surgeen2026-07-13T00:00:00.000ZThe High-Volume OPD Problem: Why Indian Clinical Documentation Requires a Purpose-Built Artificial Intelligence Modelhttps://www.pharmaradar360.com/article/drug-of-abuse-screening-in-the-era-of-poct-a-persistent-technological-gap-61ede9483a6427bdPharma Surgeen2026-07-13T00:00:00.000ZDrug-of-abuse screening in the era of POCT: a persistent technological gaphttps://www.pharmaradar360.com/article/la-constitucion-de-1824-y-la-extincion-de-la-fisicatura-mor-impactos-en-la-ensen-622247ab2f907850Pharma Surgeen2026-07-13T00:00:00.000ZLa Constitución de 1824 y la extinción de la Fisicatura-mor: impactos en la enseñanza de farmacia y en la fiscalización del mercado de medicamentoshttps://www.pharmaradar360.com/article/laparoscopic-repair-of-a-rare-morgagni-hernia-a-case-report-af3ce262350005b7Pharma Surgeen2026-07-13T00:00:00.000ZLaparoscopic repair of a rare Morgagni hernia: A case reporthttps://www.pharmaradar360.com/article/integrative-strategies-in-herbal-product-based-drug-discovery-from-computational-5dfa786280f7d6ebPharma Surgeen2026-07-13T00:00:00.000ZIntegrative strategies in herbal product-based Drug discovery: from computational models to molecular insightshttps://www.pharmaradar360.com/article/the-efficacy-safety-and-impact-of-various-clinical-pathological-characteristics-85bb3c71133540bfPharma Surgeen2026-07-13T00:00:00.000ZThe efficacy, safety, and impact of various clinical-pathological characteristics on the adjuvant immune checkpoint blockade in resected melanomahttps://www.pharmaradar360.com/article/the-glycolysis-h4k12la-pkm2-positive-feedback-loop-drives-m2-polarization-of-mac-624f473ff1124db8Pharma Surgeen2026-07-13T00:00:00.000ZThe glycolysis-H4K12la-PKM2 positive feedback loop drives M2 polarization of macrophages in colorectal cancerhttps://www.pharmaradar360.com/article/designing-clinical-research-on-hyperbaric-oxygen-therapy-a-narrative-review-and-af6d27e61dd96918Pharma Surgeen2026-07-13T00:00:00.000ZDesigning clinical research on hyperbaric oxygen therapy: a narrative review and practical methodological guidehttps://www.pharmaradar360.com/article/baseline-peripheral-blood-immune-markers-associated-with-clinical-outcomes-in-pa-1ccd6d45b901acffPharma Surgeen2026-07-13T00:00:00.000ZBaseline peripheral blood immune markers associated with clinical outcomes in patients with advanced breast cancer treated with trastuzumab deruxtecanhttps://www.pharmaradar360.com/article/the-impact-of-spiritual-care-on-gestational-diabetes-self-management-a-randomize-23c64d4fa5a5632dPharma Surgeen2026-07-13T00:00:00.000ZThe impact of spiritual care on gestational diabetes self-management: a randomized controlled trialhttps://www.pharmaradar360.com/article/effect-of-preoperative-isometric-hand-exercise-on-vascular-caliber-in-patients-w-972976891118d4b2Pharma Surgeen2026-07-13T00:00:00.000ZEffect of preoperative isometric hand exercise on vascular caliber in patients with advanced chronic kidney disease - a randomised controlled trialhttps://www.pharmaradar360.com/article/adaptive-gaussian-process-search-for-simulation-based-sample-size-estimation-in-f91338caa94fb0fdPharma Surgeen2026-07-13T00:00:00.000ZAdaptive Gaussian process search for simulation-based sample size estimation in clinical prediction models: validation of the pmsims R packagehttps://www.pharmaradar360.com/article/a-nomogram-for-predicting-buccal-bone-coverage-at-the-implant-shoulder-in-bone-a-1b4a15b161adca36Pharma Surgeen2026-07-13T00:00:00.000ZA Nomogram for Predicting Buccal Bone Coverage at the Implant Shoulder in Bone Augmentation Using the Full‐Thickness Envelope Flap Technique: A Retrospective Cohort Studyhttps://www.pharmaradar360.com/article/comment-on-lebrikizumab-provides-stable-skin-response-with-no-or-minimal-fluctua-fef381a388fabf1dPharma Surgeen2026-07-13T00:00:00.000ZComment on ‘Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis’https://www.pharmaradar360.com/article/vibrational-spectroscopy-of-clinical-biofluids-advances-in-ftir-and-raman-based-f8745025c8f91801Pharma Surgeen2026-07-13T00:00:00.000ZVibrational Spectroscopy of Clinical Biofluids: Advances in FTIR and Raman-Based Biomarker Discovery for Disease Diagnosis and Monitoringhttps://www.pharmaradar360.com/article/the-role-of-medium-intensity-training-in-promoting-functional-independence-and-c-f7a9918b9c73311dPharma Surgeen2026-07-13T00:00:00.000ZThe role of medium-intensity training in promoting functional independence and cognitive function in older adults: a randomized controlled trialhttps://www.pharmaradar360.com/article/drug-tolerant-persisters-to-trail-emerge-from-a-dose-dependent-surface-in-a-cell-7412d2036e31785dPharma Surgeen2026-07-13T00:00:00.000ZDrug-tolerant persisters to TRAIL emerge from a dose-dependent surface in a cell-state continuum of sensitivityhttps://www.pharmaradar360.com/article/glucagon-like-peptide-1-receptor-activation-and-mental-health-a-drug-target-mend-eab8b6b22a76fd8ePharma Surgeen2026-07-13T00:00:00.000ZGlucagon-like peptide-1 receptor activation and mental health: a drug-target mendelian randomization studyhttps://www.pharmaradar360.com/article/randomized-phase-2-trial-of-cpx-351-vs-clag-m-cladribine-cytarabine-g-csf-and-mi-c6bf32f4fb0a239ePharma Surgeen2026-07-13T00:00:00.000ZRandomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasmshttps://www.pharmaradar360.com/article/effects-of-a-low-glycemic-moderately-carbohydrate-restricted-diet-on-hepatic-lip-f2549ed1714ab5aePharma Surgeen2026-07-13T00:00:00.000ZEffects of a low-glycemic, moderately-carbohydrate restricted diet on hepatic lipid content and insulin sensitivity in adolescents with MASLD: protocol of a 6-month family-based, randomized controlled trialhttps://www.pharmaradar360.com/article/medical-affairs-in-the-age-of-complexity-from-scientific-support-to-strategic-en-2466a79f304fb5b4Pharma Surgeen2026-07-13T00:00:00.000ZMedical Affairs in the Age of Complexity: From Scientific Support to Strategic Enterprise Integratorhttps://www.pharmaradar360.com/article/sexual-dysfunction-among-males-living-with-hiv-receiving-dolutegravir-based-anti-93806c851348fcf5Pharma Surgeen2026-07-13T00:00:00.000ZSexual Dysfunction Among Males Living with HIV Receiving Dolutegravir-Based Antiretroviral Therapy in Uganda: A Cross-sectional Studyhttps://www.pharmaradar360.com/article/phytocompounds-with-immunomodulatory-activities-mechanisms-therapeutic-potential-bd4321a2431bd944Pharma Surgeen2026-07-13T00:00:00.000ZPhytocompounds with immunomodulatory activities: mechanisms, therapeutic potential, and clinical prospectshttps://www.pharmaradar360.com/article/distinct-clinical-characteristics-and-prognostic-factors-of-pediatric-meningioma-90688938791487abPharma Surgeen2026-07-13T00:00:00.000ZDistinct clinical characteristics and prognostic factors of pediatric meningiomas in a 10-year cohort of 198 patientshttps://www.pharmaradar360.com/article/flow-diversion-in-proximal-superior-cerebellar-artery-aneurysms-systematic-revie-49ff0d6539473961Pharma Surgeen2026-07-13T00:00:00.000ZFlow diversion in proximal superior cerebellar artery aneurysms: Systematic review of clinical outcomes and exploratory hemodynamic analysishttps://www.pharmaradar360.com/article/clinical-predictors-microbiological-profile-and-outcomes-of-bacteremia-in-patien-b885c0ffc683ea69Pharma Surgeen2026-07-13T00:00:00.000ZClinical predictors, microbiological profile, and outcomes of bacteremia in patients with cellulitis: a 6-year retrospective cohort studyhttps://www.pharmaradar360.com/article/airway-risk-in-angioedema-validation-of-a-clinical-triage-algorithm-for-ent-refe-d23b2f3fdeb12430Pharma Surgeen2026-07-13T00:00:00.000ZAirway Risk in Angioedema: Validation of a Clinical Triage Algorithm for ENT Referralhttps://www.pharmaradar360.com/article/what-counts-as-educational-innovation-in-clinical-anatomy-385ddda569886c89Pharma Surgeen2026-07-13T00:00:00.000ZWhat Counts as Educational Innovation in Clinical Anatomy?https://www.pharmaradar360.com/article/nct07699835-efficacy-of-a-gamified-blended-mindfulness-program-to-reduce-burnout-54e3a4dbf51feb7fPharma Surgeen2026-07-13T00:00:00.000ZNCT07699835: Efficacy of a Gamified Blended Mindfulness Program to Reduce Burnout, Stress, and Anxiety in Nursing Students: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/nct07699562-icu-connect-study-comparing-emg-in-healthy-volunteers-and-icu-patien-4f90522778587cfcPharma Surgeen2026-07-13T00:00:00.000ZNCT07699562: ICU CONNECT: Study Comparing EMG in Healthy Volunteers and ICU Patients.https://www.pharmaradar360.com/article/nct07699315-preoperative-dexamethasone-injection-to-improve-local-anesthesia-suc-4fded514f6467d8aPharma Surgeen2026-07-13T00:00:00.000ZNCT07699315: Preoperative Dexamethasone Injection to Improve Local Anesthesia Success in Endodontic Treatmenthttps://www.pharmaradar360.com/article/nct07699211-dalbavancin-therapy-for-infective-endocarditis-2f143320a2106826Pharma Surgeen2026-07-13T00:00:00.000ZNCT07699211: Dalbavancin Therapy for Infective Endocarditishttps://www.pharmaradar360.com/article/nct07698756-a-clinical-study-of-hrs-8797-in-healthy-participants-928bf90a97747a4fPharma Surgeen2026-07-13T00:00:00.000ZNCT07698756: A Clinical Study of HRS-8797 in Healthy Participantshttps://www.pharmaradar360.com/article/nct07698210-a-study-of-ly4178256-in-healthy-participants-023701b6ea3244a6Pharma Surgeen2026-07-13T00:00:00.000ZNCT07698210: A Study of LY4178256 in Healthy Participantshttps://www.pharmaradar360.com/article/nct07697560-safety-tolerability-and-pk-of-ah-008-following-single-ascending-dose-b5b538fd1730dd51Pharma Surgeen2026-07-13T00:00:00.000ZNCT07697560: Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy Subjectshttps://www.pharmaradar360.com/article/nct07697105-effectiveness-of-the-telemonitoring-program-for-patients-with-chroni-a3c334b251325573Pharma Surgeen2026-07-13T00:00:00.000ZNCT07697105: Effectiveness of the Telemonitoring Program for Patients With Chronic Obstructive Pulmonary Disease (COPD)https://www.pharmaradar360.com/article/nct07697079-combination-of-ct-and-ultrasound-radiomics-combined-with-liquid-biop-33021521b82a6d3bPharma Surgeen2026-07-13T00:00:00.000ZNCT07697079: Combination of CT and Ultrasound Radiomics Combined With Liquid Biopsy to Predict Neoadjuvant Chemotherapy Response in Patients With Locally Advanced Gastric Cancerhttps://www.pharmaradar360.com/article/nct07679893-phase-2-clinical-trial-of-mnkd-201-nintedanib-dry-powder-inhalation-0d0f6126b82aabe0Pharma Surgeen2026-07-13T00:00:00.000ZNCT07679893: Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosishttps://www.pharmaradar360.com/article/nct07643272-a-study-on-the-effect-of-food-and-proton-pump-inhibitor-on-the-pharm-43be20678f8a2456Pharma Surgeen2026-07-13T00:00:00.000ZNCT07643272: A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsuleshttps://www.pharmaradar360.com/article/nct07526896-advancing-clinical-heart-failure-outcomes-leveraging-defibrillation-04f89a57f412aadePharma Surgeen2026-07-13T00:00:00.000ZNCT07526896: Advancing Clinical Heart Failure Outcomes Leveraging Defibrillation Lead Implant System for Left Bundle Branch Area Pacinghttps://www.pharmaradar360.com/article/nct07525544-a-study-to-investigate-the-safety-and-pk-of-vh4770359-in-healthy-par-fb1e67b120bee821Pharma Surgeen2026-07-13T00:00:00.000ZNCT07525544: A Study to Investigate the Safety and PK of VH4770359 in Healthy Participantshttps://www.pharmaradar360.com/article/nct07444424-a-study-to-investigate-the-effect-of-azd5004-on-mitiglinide-and-piog-259e554bf87e1d3fPharma Surgeen2026-07-13T00:00:00.000ZNCT07444424: A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participantshttps://www.pharmaradar360.com/article/nct07302347-a-study-of-pembrolizumab-in-japanese-pediatric-participants-with-sol-339e837cfca53bfdPharma Surgeen2026-07-13T00:00:00.000ZNCT07302347: A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)https://www.pharmaradar360.com/article/nct07242469-a-clinical-trial-of-mk-1403-in-participants-with-type-2-diabetes-mel-01ebc13b380a10f0Pharma Surgeen2026-07-13T00:00:00.000ZNCT07242469: A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)https://www.pharmaradar360.com/article/nct07151378-intestinal-levodopa-entacapone-therapy-lecigon-to-counteract-dopamin-f62d29ef8d4b3500Pharma Surgeen2026-07-13T00:00:00.000ZNCT07151378: Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Diseasehttps://www.pharmaradar360.com/article/nct07117630-an-open-label-bayesian-adaptive-phase-ii-clinical-study-in-hr-her2-a-a96ce4319d18435dPharma Surgeen2026-07-13T00:00:00.000ZNCT07117630: An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapyhttps://www.pharmaradar360.com/article/nct07073547-a-phase-i-open-label-multicenter-study-to-evaluate-the-safety-tolera-81dee05d35025cf6Pharma Surgeen2026-07-13T00:00:00.000ZNCT07073547: A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)https://www.pharmaradar360.com/article/nct07061964-combining-immunotherapy-and-radiation-therapy-to-help-patients-avoid-ad1818cfbf369e2cPharma Surgeen2026-07-13T00:00:00.000ZNCT07061964: Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trialhttps://www.pharmaradar360.com/article/nct07024732-a-safety-and-tolerability-clinical-trial-of-pst-611-in-dry-age-relat-e8633186bf5f081dPharma Surgeen2026-07-13T00:00:00.000ZNCT07024732: A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular Degenerationhttps://www.pharmaradar360.com/article/nct06991751-a-natural-history-of-cardiometabolic-disease-among-us-bhutanese-deve-74080274b3baf1daPharma Surgeen2026-07-13T00:00:00.000ZNCT06991751: A Natural History of Cardiometabolic Disease Among US Bhutanese: Developing the Cross-Sectional Bhutanese Community of Central Ohio Health Study to Understand Acculturation as Synergizing Socioenvironmental and Biobehavioral Risk Factors Propagating ...https://www.pharmaradar360.com/article/nct06980428-a-study-to-investigate-safety-tolerability-pharmacokinetics-and-phar-56596096b2346d2bPharma Surgeen2026-07-13T00:00:00.000ZNCT06980428: A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemiahttps://www.pharmaradar360.com/article/nct06765109-neladalkib-nvl-655-for-tki-naive-patients-with-advanced-alk-positive-02b85dbc4e82adf0Pharma Surgeen2026-07-13T00:00:00.000ZNCT06765109: Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLChttps://www.pharmaradar360.com/article/nct06526988-implementation-and-interaction-of-clinician-and-patient-facing-tools-13fffbc9267302a5Pharma Surgeen2026-07-13T00:00:00.000ZNCT06526988: Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failurehttps://www.pharmaradar360.com/article/nct06337318-comparing-rituximab-and-mosunetuzumab-drug-treatments-for-people-wit-f9c0f74dff068b0ePharma Surgeen2026-07-13T00:00:00.000ZNCT06337318: Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphomahttps://www.pharmaradar360.com/article/nct06336330-real-world-study-on-dapagliflozin-usage-in-patients-with-heart-failu-3cb8c2e7daff62cfPharma Surgeen2026-07-13T00:00:00.000ZNCT06336330: Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germanyhttps://www.pharmaradar360.com/article/nct06203600-adding-nivolumab-to-usual-treatment-for-people-with-advanced-stomach-520cb5d107702f36Pharma Surgeen2026-07-13T00:00:00.000ZNCT06203600: Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trialhttps://www.pharmaradar360.com/article/nct06058377-adding-an-immunotherapy-drug-medi4736-durvalumab-to-the-usual-chemot-2e48b979fc6c9737Pharma Surgeen2026-07-13T00:00:00.000ZNCT06058377: Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancerhttps://www.pharmaradar360.com/article/nct06037954-a-study-of-mental-health-care-in-people-with-cancer-865694e289c4e6d8Pharma Surgeen2026-07-13T00:00:00.000ZNCT06037954: A Study of Mental Health Care in People With Cancerhttps://www.pharmaradar360.com/article/nct05995665-assistive-soft-robotic-glove-esoglove-intervention-for-stroke-patien-7f01234b525569b2Pharma Surgeen2026-07-13T00:00:00.000ZNCT05995665: Assistive Soft Robotic Glove (EsoGLOVE) Intervention for Stroke Patientshttps://www.pharmaradar360.com/article/nct05859204-impact-of-exercise-groups-on-patient-mental-health-and-wellbeing-in-55451a6aabf9ddfePharma Surgeen2026-07-13T00:00:00.000ZNCT05859204: Impact of Exercise Groups on Patient Mental Health and Wellbeing in an Acute Psychiatric Inpatient Unithttps://www.pharmaradar360.com/article/nct05487599-a-clinical-trial-of-pr001-ly3884961-in-patients-with-peripheral-mani-dd4c96b7f5df0d4dPharma Surgeen2026-07-13T00:00:00.000ZNCT05487599: A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)https://www.pharmaradar360.com/article/nct05467176-a-multi-center-prospective-observational-study-of-patients-being-tre-ef80ac2e06a28e17Pharma Surgeen2026-07-13T00:00:00.000ZNCT05467176: A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYXhttps://www.pharmaradar360.com/article/nct05437588-neural-derived-plasma-exosomal-micrornas-as-promising-novel-biomarke-3042838d941ed17bPharma Surgeen2026-07-13T00:00:00.000ZNCT05437588: Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescentshttps://www.pharmaradar360.com/article/nct05301842-evaluate-durvalumab-and-tremelimumab-lenvatinib-in-combination-with-2602c3adbae44632Pharma Surgeen2026-07-13T00:00:00.000ZNCT05301842: Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCChttps://www.pharmaradar360.com/article/nct04826757-effectiveness-of-coordinated-care-to-reduce-the-prolonged-disability-ad4e05e281a039edPharma Surgeen2026-07-13T00:00:00.000ZNCT04826757: Effectiveness of Coordinated Care to Reduce the Prolonged Disability Risk Among Patients Suffering From Low Back Pain in Primary Carehttps://www.pharmaradar360.com/article/nct04174742-self-reported-pain-in-women-while-undergoing-treatment-for-non-metas-f12fb4c297a5f254Pharma Surgeen2026-07-13T00:00:00.000ZNCT04174742: Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancerhttps://www.pharmaradar360.com/article/nct03736590-clinic-based-financial-coaching-and-family-health-and-development-79eeecefe5ebdb42Pharma Surgeen2026-07-13T00:00:00.000ZNCT03736590: Clinic-Based Financial Coaching and Family Health and Developmenthttps://www.pharmaradar360.com/article/nct01341145-physical-fitness-cardiovascular-and-brain-health-7c72644e32edc89fPharma Surgeen2026-07-13T00:00:00.000ZNCT01341145: Physical Fitness, Cardiovascular and Brain Healthhttps://www.pharmaradar360.com/article/hlb-determined-to-retry-liver-cancer-drug-approval-multiple-cases-of-fda-approva-61eaf1b3ad4dde74Pharma Surgeen2026-07-12T23:57:26.000ZHLB Determined to Retry Liver Cancer Drug Approval: "Multiple Cases of FDA Approval After Three CRLs"https://www.pharmaradar360.com/article/aribio-secures-90-billion-won-from-fuxing-as-ar1001-nears-phase-3-topline-chosun-06d96ae433fc87c0Pharma Surgeen2026-07-12T23:56:00.000ZAribio secures 90 billion won from Fuxing as AR1001 nears phase 3 topline - CHOSUNBIZhttps://www.pharmaradar360.com/article/u-s-fda-approves-padcev-plus-keytruda-as-neoadjuvant-and-adjuvant-treatment-for-b323af9cd44343baPharma Surgeen2026-07-12T23:30:00.000ZU.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibilityhttps://www.pharmaradar360.com/article/public-alert-no-034-2026-niger-republic-imposes-import-ban-on-bulmex-parboiled-r-640ba2d16600898bPharma Surgeen2026-07-12T19:44:13.000ZPublic Alert No. 034/2026 – Niger Republic Imposes Import Ban on Bulmex Parboiled Rice from India due to Metallic Contaminationhttps://www.pharmaradar360.com/article/over-100-food-ingredients-entered-the-us-food-supply-without-fda-safety-reviews-a513bc6d10b07799Pharma Surgeen2026-07-12T19:43:23.000ZOver 100 food ingredients entered the US food supply without FDA safety reviews, report findshttps://www.pharmaradar360.com/article/astrazeneca-turns-to-china-for-molecule-that-might-top-new-merck-copd-drug-a51716b9902a55d2Pharma Surgeen2026-07-12T19:37:17.000ZAstraZeneca Turns to China for Molecule That Might Top New Merck COPD Drughttps://www.pharmaradar360.com/article/ascelia-pharma-defends-orviglance-trial-after-fda-rejection-shares-plunge-79-in-fe941f737e31acedPharma Surgeen2026-07-12T17:35:00.000ZAscelia Pharma Defends Orviglance Trial After FDA Rejection, Shares Plunge 79% in 2026https://www.pharmaradar360.com/article/silence-therapeutics-pv-data-could-wake-the-stock-initiating-buy-nasdaq-sln-d5f9e3d267039972Pharma Surgeen2026-07-12T17:21:11.000ZSilence Therapeutics: PV Data Could Wake The Stock (Initiating Buy) (NASDAQ:SLN)https://www.pharmaradar360.com/article/fda-to-adjust-food-safety-measures-94050f429ff098fcPharma Surgeen2026-07-12T16:00:00.000ZFDA to adjust food safety measureshttps://www.pharmaradar360.com/article/mmj-the-voice-dea-didn-t-want-to-hear-from-during-marijuana-rescheduling-hearing-332ac3b3fe00432aPharma Surgeen2026-07-12T15:56:52.000ZMMJ The Voice DEA Didn't Want to Hear From During Marijuana Rescheduling Hearingshttps://www.pharmaradar360.com/article/leqembi-subcutaneous-autoinjector-clinical-data-supports-similar-efficacy-and-sa-b27c055b0052785aPharma Surgeen2026-07-12T15:30:11.000ZLEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026https://www.pharmaradar360.com/article/helus-pharma-rated-speculative-buy-ahead-of-key-phase-3-trial-results-in-2026-fo-aeb6e5a6cb03c3d4Pharma Surgeen2026-07-12T14:06:14.000ZHelus Pharma rated speculative Buy ahead of key Phase 3 trial results in 2026 for depression drug HLP003.https://www.pharmaradar360.com/article/pharmaceutical-marketplaces-how-online-platforms-are-changing-drug-purchasing-83e344e8d4cfccb7Pharma Surgeen2026-07-12T11:02:28.000ZPharmaceutical marketplaces: How online platforms are changing drug purchasinghttps://www.pharmaradar360.com/article/blood-brain-barrier-crossed-denali-s-fda-approval-unlocks-alzheimer-s-pipeline-23e98e5bcde8a841Pharma Surgeen2026-07-12T10:57:01.000ZBlood-Brain Barrier Crossed: Denali’s FDA Approval Unlocks Alzheimer’s Pipelinehttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-sichuan-goldstone-asia-pharmaceutical-inc-7a4105ab94b234bcPharma Surgeen2026-07-12T10:29:59.000ZEnterprise value to EBITDA forward of Sichuan Goldstone Asia Pharmaceutical, Inc. Class A – SZSE:300434https://www.pharmaradar360.com/article/etfs-investing-in-anhui-huaren-health-pharmaceutical-co-ltd-class-a-stocks-2b4537dd3eef3a1cPharma Surgeen2026-07-12T09:59:06.000ZETFs Investing in Anhui Huaren Health Pharmaceutical Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/abivax-s-obefazimod-met-primary-endpoint-in-phase-iii-abtect-trial-71c3cfb3242993a8Pharma Surgeen2026-07-12T09:55:52.000ZAbivax’s obefazimod met primary endpoint in Phase III ABTECT trialhttps://www.pharmaradar360.com/article/read-news-and-stories-about-faculty-of-pharmaceutical-medicine-f1c9672640bece4aPharma Surgeen2026-07-12T09:53:15.000ZRead News and Stories about Faculty of Pharmaceutical Medicinehttps://www.pharmaradar360.com/article/this-biotech-stock-could-surge-93-after-a-breakthrough-in-cancer-treatment-0cc30259ac27bc52Pharma Surgeen2026-07-12T09:51:55.000ZThis biotech stock could surge 93% after a breakthrough in cancer treatmenthttps://www.pharmaradar360.com/article/why-maharashtra-fda-flagged-cadila-pharmaceuticals-for-branding-concerns-a8ec48d6d8942ee6Pharma Surgeen2026-07-12T09:48:59.000ZWhy Maharashtra FDA Flagged Cadila Pharmaceuticals for Branding Concernshttps://www.pharmaradar360.com/article/orion-stock-reflects-steady-pharma-strategy-as-helsinki-listed-drug-maker-leans-23664a8a64ddaae3Pharma Surgeen2026-07-12T09:39:41.000ZOrion stock reflects steady pharma strategy as Helsinki-listed drug maker leans on specialty medicinhttps://www.pharmaradar360.com/article/chinese-drug-manufacturer-with-ccp-ties-imported-unauthorized-glp-1-drug-ingredi-ecde6f162642a72dPharma Surgeen2026-07-12T09:00:00.000ZChinese drug manufacturer with CCP ties imported unauthorized GLP-1 drug ingredientshttps://www.pharmaradar360.com/article/flour-crisis-looms-permit-dispute-threatens-supply-in-rawalpindi-and-islamabad-781357e1fe52c7a7Pharma Surgeen2026-07-12T08:36:00.000ZFlour Crisis Looms: Permit Dispute Threatens Supply in Rawalpindi and Islamabadhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-trinity-biotech-plc-sponsored-adr-fwb-trb0-daa730ea9f0b2f2ePharma Surgeen2026-07-12T08:34:08.000ZPrice to earnings forward of Trinity Biotech plc Sponsored ADR – FWB:TRB0https://www.pharmaradar360.com/article/a-subsidiary-product-of-northeast-pharmaceutical-000597-sz-has-been-newly-includ-4de40458109b17bcPharma Surgeen2026-07-12T08:29:33.000ZA subsidiary product of Northeast Pharmaceutical (000597.SZ) has been newly included in the National Essential Medicines List (2026 Edition).https://www.pharmaradar360.com/article/chinese-biotech-mindrank-secures-52m-to-advance-ai-designed-oral-glp-1ra-e573f03c371ce830Pharma Surgeen2026-07-12T07:29:00.000ZChinese biotech MindRank secures $52m to advance AI-designed oral GLP-1RAhttps://www.pharmaradar360.com/article/genmab-stock-reflects-the-biotech-group-s-global-oncology-ambitions-bb45e91c618f27eaPharma Surgeen2026-07-12T07:02:01.000ZGenmab stock reflects the biotech group's global oncology ambitionshttps://www.pharmaradar360.com/article/rs-2-45-crore-worth-of-aciloc-150-300-seized-in-maharashtra-fda-orders-recall-817a001962e8428fPharma Surgeen2026-07-12T07:02:00.000ZRs 2.45 crore worth of Aciloc 150+, 300+ seized in Maharashtra; FDA orders recallhttps://www.pharmaradar360.com/article/we-have-better-antihistamines-6e6b4cbc32badb6fPharma Surgeen2026-07-12T07:00:00.000ZWe have better antihistamineshttps://www.pharmaradar360.com/article/denecimig-shows-consistent-safety-and-efficacy-across-age-groups-in-hemophilia-a-18270a14d6c445c6Pharma Surgeen2026-07-12T06:53:57.000ZDenecimig shows consistent safety and efficacy across age groups in hemophilia A trialhttps://www.pharmaradar360.com/article/checkpoint-inhibitors-are-failing-recurrent-gbm-this-phase-1-trial-design-may-ex-d549d12d423f72e4Pharma Surgeen2026-07-12T06:48:57.000ZCheckpoint Inhibitors Are Failing Recurrent GBM. This Phase 1 Trial Design May Explain Why They Keep Trying.https://www.pharmaradar360.com/article/how-to-write-a-biotech-internship-email-in-2026-templates-examples-expert-tips-0886af1558fecfaePharma Surgeen2026-07-12T06:18:15.000ZHow to Write a Biotech Internship Email in 2026? Templates, Examples & Expert Tipshttps://www.pharmaradar360.com/article/maharashtra-fda-warns-against-three-cosmetics-after-mercury-lead-levels-exceed-s-d85f9dc4626795d6Pharma Surgeen2026-07-12T06:15:52.000ZMaharashtra FDA Warns Against Three Cosmetics After Mercury, Lead Levels Exceed Safety Limitshttps://www.pharmaradar360.com/article/fda-maharashtra-cracks-down-on-deceptive-drug-branding-ff534f22f6097385Pharma Surgeen2026-07-12T06:13:15.000ZFDA Maharashtra Cracks Down on Deceptive Drug Branding